Study of Tetrathiomolybdate in Patients With Wilson Disease
Part of paid clinical trials in Ann Arbor, Michigan.
- Sponsor
- National Center for Research Resources (NCRR)
- Study ID
- NCT00004339
- Phase
- PHASE3
- Status
- Completed
Conditions
- Wilson Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 0 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- tetrathiomolybdate — DRUG
- trientine — DRUG
Study Details
OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically.
Key Dates
- First listed
- Oct 19, 1999
- Start date
- Jan 31, 1994
- Status verified
- Dec 2003
Study Design
- Enrollment
- 90 participants
- Allocation
- RANDOMIZED
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Michigan | Ann Arbor | Michigan | 48109 | - |
Find similar trials in Ann Arbor, MI
By research site
Related Studies
- Natural History of Wilson DiseaseRecruiting · Yale University · New Haven, Connecticut
- Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot StudyRecruiting · Yale University · New Haven, Connecticut